Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

to our Phase IIb clinical trial for TRU-015, increased personnel- related expenses due to increased headcount, and increased outside manufacturing costs related to our TRU-016 product candidate. These increases were partially offset by lower outside manufacturing costs for TRU-015 due to the successful transfer of manufacturing activities to Wyeth during 2007 and lower noncash stock-based compensation charges.

Net loss for the third quarter and nine months ended Sept. 30, 2007, was $5.9 million, or $0.33 per diluted common share, and $18.4 million, or $1.04 per diluted common share, respectively, compared with net income of $5.4 million, or $0.40 per diluted common share, and $871,000, or $0.06 per diluted common share respectively in 2006.

Trubion had $86.6 million in cash, cash equivalents and investments as of Sept. 30, 2007, compared with $90.3 million as of June 30, 2007.

"We are pleased with our progress in the third quarter," said Peter Thompson, M.D., FACP, Trubion's president, chief executive officer and chairman. "We continued to advance the development of multiple product candidates and reported positive preliminary results of our Phase IIb trial evaluating TRU-015 for the treatment of Rheumatoid Arthritis. In the fourth quarter we expect to begin TRU-015 Phase I clinical trials for both Systemic Lupus Erythematosus and non-Hodgkin's lymphoma, and have recently filed an investigational new drug application for our proprietary candidate, TRU-016 for B-cell malignancies."

2007 Financial Guidance

As a result of lower anticipated reimbursement revenue and lower expenses due primarily to the successful transfer of manufacturing activities for TRU-015 from Trubion to Wyeth, the company expects 2007 results to fall within the low end of, or slightly below, its previously provided ranges. The guidance ranges previously provided by the company include:

-- Revenue - $20 million to $25 million. Revenue is generated from fees,


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Portal Solutions , a technology consulting firm ... Office 365 and SharePoint platforms , today announces its inclusion ... one of the region’s fastest-growing mid-sized companies based on a ... “To be recognized a second year in a row by ...
(Date:1/22/2015)... 2015 GEA Niro Soavi the leader ... homogenizer, the PandaPLUS 2000, which is ideal for new ... cell disruption . This compact laboratory homogenizer is ... liquid food, food additives and ingredients as well as ...
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... CHICAGO, July 3 Advanced Life Sciences,Holdings, ... company engaged in the,discovery, development and commercialization ... infection, cancer and respiratory diseases, today,announced that ... Index after the,Russell Investment Group reconstituted its ...
... -- Huifeng,Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: ... extracts and pharmaceutical raw materials,for use in ... today that its company information will be ... Program, an information distribution,service that enables subscribing ...
... choice of two distinct drugs on ... separate drug-eluting stent platforms, NATICK, Mass., July ... that the U.S. Food and Drug,Administration (FDA) has approved the ... disease. The,PROMUS Stent is a private-labeled XIENCE(TM) V Everolimus-Eluting Coronary,Stent ...
Cached Biology Technology:Advanced Life Sciences Added to Russell Microcap Index 2Advanced Life Sciences Added to Russell Microcap Index 3Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... University of Hawaii at Manoa,s School of Ocean Earth ... of Sea Disposal Site Hawaii Number 5 (HI-05), a ... approximately 5 miles south of Pearl Harbor, Oahu, Hawaii. ... sidescan sonar and remotely operated underwater vehicles to locate ...
... in Spanish . Agricultural Research Service ... genetics of a native prairie grass being widely studied for ... switchgrass, published by Christian Tobias, a molecular biologist at the ... colleagues, is expected to speed up the search for genes ...
... the genetics in humans and fish, scientists now believe that ... and shoulders gave humans so much freedom of movement ... evolution of the human brain, according to New York University ... Communications (July 27, 2010.) Scientists had assumed ...
Cached Biology News:University of Hawaii completes 3-year investigation of military munitions sea disposal site 2University of Hawaii completes 3-year investigation of military munitions sea disposal site 3A new tool for improving switchgrass 2
... for analytical performance , ... the ultimate in analytical,performance, the ... 810-MS features include: , ... providing reliable, routine, trace level,quantification. ...
... high-performance ICP-MS system designed for flexibility and ... II off-axis ion lens, true hyperbolic quadrupole ... handle the widest range of sample types ... now includes as standard Agilents unique ShieldTorch ...
... Identical to the DH-2000, except that it ... 190-1700 nm wavelength range and comes with a ... up to 5 Hz) The DH-2000 ... spectrum of deuterium and tungsten halogen light sources ...
... a fully automated microplate luminescence reader ... possible range of applications based on ... luciferase, -galactosidase, gene activities with luminescence ... Luminescent Immunoassays Cell-based assays (cytotoxity ...
Biology Products: